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RESEARCH
Surgical treatments for men with benign prostatic
enlargement: cost effectiveness study
Nigel Armstrong, health economist,1 Luke Vale, professor of health technology assessment,2 Mark Deverill,
senior research fellow,1 Ghulam Nabi, clinical lecturer,3 Samuel McClinton, consultant urologist,3 James
N’Dow, professor of urology,3 Robert Pickard, senior clinical lecturer,4 for the BPE Study Groupfor the BPE
Study Group
ABSTRACT
Objective To determine which surgical treatment for lower
urinary tract symptoms suggestive of benign prostate
enlargement is cost effective.
Design Care pathways describing credible treatment
strategies were decided by consensus. Cost-utility
analysis used Markov modelling and Monte Carlo
simulation.
Data sources Clinical effectiveness data came from a
systematic review and an individual level dataset. Utility
values came from previous economic evaluations. Costs
were calculated from National Health Service (NHS) and
commercial sources.
Methods The Markov model included parameters with
associated measures of uncertainty describing health
states between which individuals might move at three
monthly intervals over 10 years. Successive annual
cohorts of 25000 men were entered into the model and
the probability that treatment strategies were cost
effective was assessed with Monte Carlo simulation with
10000 iterations.
Results A treatment strategy of initial diathermy
vaporisation of the prostate followed by endoscopic
holmium laser enucleation of the prostate in case of
failure to benefit or subsequent relapse had an 85%
probability of being cost effective at a willingness to pay
value of £20000 (€21595, $28686)/quality adjusted life
year (QALY) gained. Other strategies with diathermy
vaporisation as the initial treatment were generally
cheaper and more effective than the current standard of
transurethral resection repeated once if necessary. The
use of potassium titanyl phosphate laser vaporisation
incurred higher costs and was less effective than
transurethral resection, and strategies involving initial
minimally invasive treatment with microwave
thermotherapy were not cost effective. Findings were
unchanged by wide ranging sensitivity analyses.
Conclusion The outcome of this economic model should
be interpreted cautiously because of the limitations of the
data used. The finding that initial vaporisation followed
by holmium laser enucleation for failure or relapse might
be advantageous both to men with lower urinary tract
symptoms and to healthcare providers requires
confirmation in a good quality prospective clinical trial
before any change in current practice. Potassium titanyl
phosphate laser vaporisation was unlikely to be cost
effective in our model, which argues against its
unrestricted use until further evidence of effectiveness
and cost reduction is obtained.
INTRODUCTION
Evaluation of treatments for chronic health conditions
requires studies of both effectiveness and cost effective-
ness over the long term to identify how best to use the
available budget. Benign prostatic enlargement caused
by hyperplasia of the gland is an inevitable and pro-
gressive accompaniment to ageing in men. It is the
main cause of lower urinary tract symptoms, such as
frequency and poor flow, with a prevalence of about
30% in men aged over 60, amounting to 1.8 million in
the United Kingdom.1 Treatments for urinary symp-
toms presumed to be caused by benign prostatic enlar-
gement control symptoms rather than lead to a cure,
giving a long term risk of disease progression despite
an initial response.2 Endoscopic removal of prostate
tissue, typically by transurethral resection (TURP), is
usually recommended to men who have not benefited
from behavioural or drug treatment as it offers a high
(70-80%) chance of benefit and a low (1% per year) risk
of retreatment. About 25 000 such procedures are car-
ried out annually in England at a cost of £53m (€57m,
$76m). Despite sustained effectiveness, transurethral
resection carries the risk of major haemorrhage and
myocardial stress.3 Consequently, alternative surgical
options have been trialled to reduce treatmentmorbid-
ity but maintain effectiveness.
In a systematic review of effectiveness we concluded
that newer technologies, such as microwave thermo-
therapy and diathermy or laser vaporisation, do
improve symptoms and reduce risk but have higher
rates of retreatment than transurethral resection.4 5
According to personal preference, men seeking treat-
ment might trade off this reduced effectiveness for the
reduced risk. For most this would result in successful
treatment but a minority would have the inconveni-
ence and exposure to risk of having to have a second
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more effective but potentiallymoremorbid procedure.
This might also give improvement from a healthcare
perspective as use of themore morbid and costly treat-
ments would be reduced. Such treatment sequences
reflect current practice, particularly in the United
States, where office based minimally invasive treat-
ments aremore widely used. Previous studies of health
economics focused on single treatments without allow-
ance for repeat or alternative treatment and provided
only limited cost breakdown and sensitivity analysis,
restricting generalisability across healthcare
systems.6-8 We modelled the use of plausible strategies
of sequential treatments to maintain symptom control
over an appropriate time span to determine which is
most likely to be cost effective.
METHODS
Model design
We constructed a Markov model to investigate cost
utility of each considered treatment option with effects
measured by quality adjusted life years (QALYs) and
costs (£) at 2006 prices discounted at 3.5%.9 The per-
spective was the UK’s NHS, with treatments taking
place in appropriately equipped hospitals served by
specialist urologists already competent to carry out
the procedures.
Treatment options and care pathways
The standard procedure was transurethral resection,
with failure to benefit or subsequent relapse managed
by a second transurethral resection carried out only if
urodynamics confirmed obstruction of the bladder
outlet. Alternative treatments were categorised into
three groups: minimally invasive, characterised by no
tissue removal and ambulatory care; tissue ablative,
signifying the use of differing energy sources to par-
tially remove prostate tissue; and near total removal
of prostate by holmium laser enucleation (HoLEP).
Appraisal of the evidence base for effectiveness,4 5 cur-
rent practice, and commercial availability identified
transurethral microwave thermotherapy (TUMT)
and diathermy vaporisation (TUVP) as typifying the
minimally invasive and tissue ablative groups, respec-
tively. We also included potassium titanyl phosphate
(KTP) laser vaporisation in themodel as a substitute for
diathermy vaporisation given its current clinical
Table 1 | Schematic illustrating 23 treatment strategies tested in model. Each treatment strategy involved sequence of
between one and five individual treatments. For each sequence “1” represents first treatment with “2,” “3,” “4,” and “5”
indicating subsequent treatments administered after treatment failure or relapse of symptoms after initial success
Microwave thermotherapy
Diathermy vaporisation*
Transurethral resection Holmium laser
enucleation1st 2nd 1st 2nd
One treatment
Strategy 1 1 — — — — —
Strategy 2 — — 1 — — —
Strategy 3 — — — 1 — —
Strategy 4 — — — — — 1
Two treatments
Strategy 5 1 2 — — — —
Strategy 6 1 — 2 — — —
Strategy 7 1 — — 2 — —
Strategy 8 1 — — — — 2
Strategy 9 — — 1 2 — —
Strategy 10 — — 1 — — 2
Strategy 11 — — — 1 2 —
Three treatments
Strategy 12 1 2 3 — — —
Strategy 13 1 2 — 3 — —
Strategy 14 1 2 — — — 3
Strategy 15 1 — 2 3 — —
Strategy 16 1 — 2 — — 3
Strategy 17 1 — — 2 3 —
Strategy 18 — — 1 2 3 —
Four treatments
Strategy 19 1 2 3 4 — —
Strategy 20 1 2 3 — — 4
Strategy 21 1 — 2 3 4 —
Strategy 22 1 2 — 3 4 —
Five treatments
Strategy 23 1 2 3 4 5 —
*Additional sequence run replacing diathermy vaporisation with potassium titanyl phosphate laser vaporisation.
RESEARCH
page 2 of 13 BMJ | ONLINE FIRST | bmj.com
 on 8 June 2009 bmj.comDownloaded from 
popularity.10 A clinical expert group, consisting of four
urologists from two centres, identified by consensus
clinically appropriate sequences of escalating surgical
intervention according to treatment mechanism and
effect on remaining prostate tissue. Sequences were
defined by a set of rules reflecting current and likely
future use of each method: treatments always pro-
ceeded from less to more invasive; minimally invasive
treatments could be repeated only once; tissue ablative
and holmium laser enucleation procedures could not
be repeated because of the effect on remaining prostate
tissue and near total removal, respectively; and trans-
urethral resection could be repeated only once and
only after confirmation of obstruction of the bladder
outlet (table 1). 11
Population of patients
Thepopulationwasmenwith symptoms (international
prostate symptom score (IPSS) >7) with presumed
benign prostatic enlargement without specification of
prostate size and no existing relevant complications,
who required transurethral resection. The mean age
was set at 70, the mid-point of the age range for men
undergoing this surgery.
Model structure
We constructed a Markov model describing the
sequence of events and main health states that men
might find themselves in after the defined treatment
strategies. The cycle length was set at three months,
the period over which benefit would occur and short
term adverse events resolve. We chose a time horizon
of 10 years as this was the period over which the popu-
lation would be likely to seek active treatment and cur-
rent technologies would remain relevant. The model
was run by entering 10 successive annual cohorts of
25 000 men, the number receiving treatment each
year in the NHS in England. We chose a multiple
cohort design to better model the effects of applying
sequences of escalating treatment and where progres-
sively fewer members of a cohort would need addi-
tional surgery. The design also simulates the purchase
of new equipment as required over the stated time hor-
izon.
Definition of health states
We defined six health states: treatment, remission, no
remission, remission with incontinence, no remission
with incontinence, and death. Remission was defined
as a more than 10% improvement in the international
prostate symptom score, equivalent, for the population
under study, to the 3 point reduction noticeable by
men undergoing treatment for symptoms presumed
to be caused by benign prostatic enlargement.12 The
number of cycles spent by each individual in this
state was determined by the probability of relapse
Table 2 | Utility values and miscellaneous risks and costs used to specify Monte Carlo simulation in decision analytical model
Condition Value* Standard error (95% CI) Source Assigned distribution
Utility values
Health states:
Remission 1.00 0 Kok et al15 Beta
No remission 0.94 0.009 (0.92 to 0.96) Kok et al15 Beta
Incontinence 0.89 0.006 (0.88 to 0.91) Ackerman et al16 Beta
Adverse effects†:
Urinary retention 0.89 0.012 (0.87 to 0.92) Ackerman et al16 Beta
Bladder neck stenosis 0.95 0.001 (0.95 to 0.96) Ackerman et al16 Beta
Urinary tract infection 0.93 0.004 (0.92 to 0.94) Ackerman et al16 Beta
Transurethral resection syndrome 0.81 0.022 (0.77 to 0.85) Ackerman et al16 Beta
Miscellaneous variables
Risks:
Transurethral resection after urinary
retention
0.5 0.05 (0.40 to 0.6) Expert opinion Beta
Urge type incontinence 0.95 0.02 (0.91 to 0.99) Expert opinion Beta
Costs:
Baseline treatment (including mean length
of stay) (£)
1862 (1546 to 2195)‡ NHS 200617 Lognormal
Urology ward bed day (£) 250 (141 to 443)‡ NHS 200617 Lognormal
Length of stay after transurethral resection
syndrome (days)
2 0.51 (1 to 3) Expert opinion Normal
Length of stay after urinary infection (days) 3 1.4 (0.25 to 5.75) Expert opinion Normal
Urodynamic test (£) 125 16 (92 to 157) NHS 200517 Normal
Transfusion (£) 1270 323 (635 to 1905) NHS tariff Normal
Oxybutynin (£) 166 (65 to 267)§ NHS drug tariff Uniform
*Risk unless otherwise stated.
†Age adjusted mortality rates estimated from UK life tables and applied equally throughout time horizon without weighting according to procedure.
‡Where log distributions have been used, standard error is omitted to avoid inconsistency with confidence interval, which is expressed as actual relative risk.
§Limits of uniform distribution.
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after an initially successful treatment derived from long
term observation data. The state of “no remission”was
entered with the probability of initial failure or subse-
quent relapse for that particular treatment. Inconti-
nence, defined as leakage of urine of sufficient degree
to make an individual seek help and therefore result in
additional treatment, was the only complication we
included in themodel. If this occurred no further treat-
ment was possible and only transitions from remission
to no remission or to death could occur. All other com-
plications (urinary retention, bladder neck stenosis
and/or urethral stricture, blood transfusion (a measure
of severe bleeding), transurethral syndrome, and urin-
ary infection) were considered as short term and were
assumed to have been resolved within the threemonth
treatment state. Retrograde ejaculation was not
included as it is generally of little trouble to the popula-
tion ofmen under study,13 and erectile dysfunctionwas
not included as incidence was similar for all inter-
ventions and for untreated men.4 5 14 Death was mod-
elled as an absorbing state with age dependent
transition probabilities calculated from UK life tables
without weighting according to procedure. If the state
of no remission-no incontinence was entered and
further treatments were possible in the defined
sequence then transition to the next treatment was
allowed. If the individual was in the no remission
state at the end of the treatment sequence then the
only transition possible was to death.
Data sources
Utility values
We derived utility values for each health state from
previous studies that used time trade-off15 and standard
gamble16 techniques, adjusted for total symptom score
and for the presence of incontinence (table 2).
Probabilities
Remission—We calculated the probability of individual
men entering the remission state after treatment as 1
−probability of relapse. We determined this probabil-
ity from an individual level dataset containing
Table 3 | Parameter values for transurethral resection and holmium laser enucleation used to specify Monte Carlo simulation in decision analytical model
Event Value* Standard error (95% CI) Source Assigned distribution
Transurethral resection parameters
Mean international prostate symptom score values:
Before treatment 22.1 0.5 (21.2 to 23.0) Individual level data18 Normal
After successful treatment 6.6 0.4 (5.9 to 7.4) Individual level data18 Normal
Risk of adverse event†:
Urinary retention 0.05 0.01 (0.04 to 0.08) Meta-analysis19 Beta
Bladder neck stenosis 0.07 0.01 (0.05 to 0.08) Meta-analysis19 Beta
Urinary tract infection 0.06 0.01 (0.05 to 0.09) Meta-analysis19 Beta
Incontinence 0.03 0.01 (0.02 to 0.05) Meta-analysis19 Beta
Transfusion 0.08 0.02 (0.05 to 0.11) Meta-analysis19 Beta
Transurethral resection syndrome 0.03 0.01 (0.01 to 0.05) Meta-analysis19 Beta
Failure at 12 months 0.06 0.02 (0.03 to 0.09) Individual level data18 Beta
Other risks:
Failure of second treatment relative to first 0.75 (0.50 to 1.00)‡ Expert opinion Uniform
Urodynamic test positive 0.75 (0.65 to 0.85)‡ Expert opinion Uniform
Reoperation at 8 years 0.08 0.01 (0.07 to 0.08) Madersbacher et al20 Beta
Holmium laser enucleation of prostate
International prostate symptom score values:
Weighted mean difference in symptom score 0.42 0.05 (0.32 to 7.35) Meta-analysis5 Normal
Relative risk of adverse event†:
Urinary retention 0.71 (0.38 to 1.32)§ Meta-analysis5 Lognormal
Bladder neck stenosis 0.84 (0.43 to 1.65)§ Meta-analysis5 Lognormal
Urinary tract infection 0.98 (0.31 to 3.09)§ Meta-analysis5 Lognormal
Incontinence 0.97 (0.72 to 1.31)§ Meta-analysis5 Lognormal
Transfusion 0.27 (0.07 to 0.95)§ Meta-analysis5 Lognormal
Transurethral resection syndrome 0.31 (0.01 to 7.39)§ Meta-analysis5 Lognormal
Failure at 12 months 0.68 (0.32 to 1.44)§ Meta-analysis5 Lognormal
Costs:
Life of machine (years) 10 (5 to 15)‡ Expert opinion Uniform
No of times optical fibre re-used 25 (20 to 30)‡ Expert opinion Uniform
No of times of morcellator blade re-used 7.5 (5 to 10)‡ Expert opinion Uniform
*Risk unless otherwise stated.
†Age adjusted mortality rates were estimated from United Kingdom life tables and applied equally throughout the time horizon without weighting according to procedure.
‡Limits of the uniform distribution.
§Where log distributions have been used, standard error is omitted to avoid inconsistency with confidence interval, which is expressed as actual relative risk
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international prostate symptom scores at baseline and
fourmonths after transurethral resection for a cohort of
179 men according to the criterion of less than 10%
improvement in symptom score.18 For other treat-
ments we derived this probability using individual
data for transurethral resection and the weighted
mean difference in the treatment effect, compared
with transurethral resection, derived from a systematic
review.4 5 Estimates of the probability of subsequent
relapse were derived from meta-analyses, long term
cohort studies, and consensus opinion from the clinical
expert group (tables 3 and4). Theprobability of failure
for subsequent treatments was estimated as if there had
been no previous treatment. If an individual treatment
such as microwave thermotherapy or transurethral
resection was used twice in a strategy then the risk of
a second failure was decided by consensus of the clin-
ical expert group.
Relapse—Relapse denoted transition from the remis-
sion to the no remission state. We calculated this for
each treatment by subtracting the respective initial fail-
ure rate derived bymeta-analysis from the total retreat-
ment rate documented in studies with long term
follow-up. Long term data were available only for
transurethral resection andmicrowave thermotherapy
and we therefore derived rates for other treatments
from these according to the weighted mean difference
in symptom score at 12 months found on meta-analy-
sis. We calculated transition probabilities of
Table 4 | Parameter values for diathermy vaporisation, potassium titanyl phosphate laser vaporisation, and microwave
thermotherapy used to specify Monte Carlo simulation in decision analytical model
Event Value* Standard error (95% CI) Source Assigned distribution
Diathermy vaporisation
Weighted mean difference in IPSS −0.18 0.23 (−0.63 to 0.26) Meta-analysis5 Normal
Relative risk of adverse event†:
Urinary retention 2.12 (1.23 to 3.68)‡ Meta-analysis5 Lognormal
Bladder neck stenosis 0.91 (0.45 to 1.85)‡ Meta-analysis5 Lognormal
Urinary tract infection 0.65 (0.40 to 1.08)‡ Meta-analysis5 Lognormal
Incontinence 0.92 (0.69 to 1.21)‡ Meta-analysis5 Lognormal
Transfusion 0.19 (0.08 to 0.44)‡ Meta-analysis5 Lognormal
Transurethral resection syndrome 0.59 (0.17 to 2.12)‡ Meta-analysis5 Lognormal
Failure at 12 months 1.04 (0.53 to 2.07)‡ Meta-analysis5 Lognormal
Potassium titanyl phosphate vaporisation‡
Weighted mean difference in IPSS −1.3 0.6 (−2.5 to (−0.1) Meta-analysis5 Normal
Relative risk of adverse event†:
Urinary retention 2.89 (1.55 to 5.42)‡ Meta-analysis5 Lognormal
Bladder neck stenosis 0.54 (0.32 to 0.90)‡ Meta-analysis5 Lognormal
Incontinence 2.24 (1.03 to 4.88)‡ Meta-analysis5 Lognormal
Transfusion 0.14 (0.05 to 0.42)‡ Meta-analysis5 Lognormal
Transurethral resection syndrome 0.33 (0.01 to 7.93)‡ Meta-analysis5 Lognormal
Urinary tract infection 1.17 (0.60 to 2.26)‡ Meta-analysis5 Lognormal
Failure at 12 months 1.68 (1.03 to 4.88)‡ Meta-analysis5 Lognormal
Life of machine (years) 10 (5 to 15)§ Expert opinion Uniform
Microwave thermotherapy
Weighted mean difference in IPSS −2.4 0.5 (−3.4 to (−1.4) Meta-analysis4 Normal
Relative risk of adverse event†:
Urinary retention 1.64 (0.77 to 3.50)‡ Meta-analysis4 Lognormal
Bladder neck stenosis 0.2 (0.05 to 0.75)‡ Meta-analysis4 Lognormal
Urinary tract infection 1.05 (0.53 to 2.08)‡ Meta-analysis4 Lognormal
Incontinence 0.61 (0.30 to 1.26)‡ Meta-analysis4 Lognormal
Transfusion 0.11 (0.01 to 1.98)‡ Meta-analysis4 Lognormal
Transurethral resection syndrome 0.65 (0.03 to 15.62)‡ Meta-analysis4 Lognormal
Failure at 12 months 2.01 (0.96 to 4.18)‡ Meta-analysis4 Lognormal
Other risks:
Failure of second treatment
relative to first
0.75 (0.50 to 1)§ Expert opinion Uniform
Reoperation at 5 years 0.36 0.01 (0.33 to 0.39) Francisca et al21 Beta
IPSS=international prostate symptom score.
*Risk unless otherwise stated.
†Age adjusted mortality rates estimated from UK life tables and applied equally throughout time horizon without weighting according to procedure.
‡Where log distributions have been used, standard error is omitted to avoid inconsistency with confidence interval, which is expressed as actual
relative risk.
§Limits of uniform distribution.
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subsequent relapse after initial treatment success for
each three month cycle, assuming a constant rate over
10 years.
Complications—We estimated probabilities for these
complications after transurethral resection by sum-
ming events across the respective treatment arms of
studies carried out in the UK. Probabilities for other
treatments were calculated with the relative risk
reported in the meta-analysis.
Mortality—Our meta-analysis22 and a previous sys-
tematic review17 showed that there was no evidence
for different mortality rates after each procedure at
12 months, while age adjusted longer term rates after
transurethral resection are known to be similar to those
in the general population.23 The only trial comparing
transurethral resection against advice on managing
symptoms alone also showed no difference in mortal-
ity rates.24 We therefore applied age specific popula-
tion mortality rates for English men, irrespective of
treatment or treatment sequence in line with previous
economic evaluations in this area.7
Costs
We considered only hospital costs because primary
care costs would be low and similar for each procedure
(tables 2, 3, 4). Endoscopic procedures (diathermy or
laser vaporisation, laser enucleation, and transurethral
resection) were assumed to incur the same basic costs
(2005 NHS reference costs for healthcare resource
group (code L28), adjusted for differing length of stay
by subtracting bed-day cost calculated from a non-
operative code (L09). We added appropriate extra
costs for equipment, such as optical fibres for laser
transmission and tissue morcellators for laser enuclea-
tion, using data provided by UK based manufacturers
or distributors. As a UK reference cost for microwave
thermotherapy was unavailable we calculated it using
manufacturers’ data from the US, day case procedure
NHS reference costs, and clinical expert opinion.
Capital costs of the relevant energy generator for
microwave thermotherapy, laser vaporisation, and
laser enucleation were derived from commercial
sources. The costs of short term complications were
calculated by summing costs of extra interventions,
such as blood transfusion or bladder neck incision,
and extra bed days calculated from the cost difference
between L27 (transurethral resection with complica-
tions) andL28 (transurethral resectionwithout compli-
cations). The cost of incontinencewas derived from the
drug tariff for oxybutyninmultiplied by the proportion
of men (95%) having urge incontinence as defined by
the clinical expert group. For the 5% ofmenwith stress
incontinence the cost was that for insertion of an artifi-
cial urinary sphincter (£6000).
Sensitivity analysis
Probabilistic
To test for the effect of uncertainty in parameter esti-
mates,we usedMonteCarlo simulation to select values
for each parameter within the model according to a
distribution around each parameter. Limits of uncer-
tainty were defined with 95% confidence intervals
from meta-analysis, the individual dataset, NHS
cost ranges, and expert opinion, with distribution
shapes chosen according to standard practice (tables 2,
3, 4).25 These values were then combined in the Mar-
kov model to estimate the outcome for each treatment
strategy by repeating the process 10 000 times and cal-
culating the expected cost and effectiveness of each
treatment sequence as the mean across all samples.
We chose the number of iterations by determining
the point at which addition of further samples did not
result in any change in the ranking. In table 5, in addi-
tion to the expected cost and effectiveness results, the
probability that a particular strategy was cost effective
was defined as the proportion of allMonte Carlo simu-
lations using that strategy meeting the willingness to
pay criterion of £20 000/QALY.9 The figure shows
results for various thresholds as a cost effectiveness
acceptability curve (figure) to illustrate uncertainty
regarding assignment of threshold values for willing-
ness to pay.
Table 5 | Cost and effectiveness data derived by Monte Carlo simulation with associated probabilities. All other non-reference strategies were dominated
Treatment strategy
Cost
(£1000s)
Incremental
cost (£1000s)
Effectiveness
(QALYs)
Incremental
effectiveness
(QALYs)
Incremental cost
effectiveness
ratio (£/QALY)
Probability of being cost effective at set willingness
to pay threshold*
£5000 £10 000 £20 000 £40 000 £80 000
Non-dominated strategies
Diathermy vaporisation 380 775 0 917 082 0 N/A 0.82 0.03 0 0 0
Holmium laser
enucleation
400 550 19 775 919 656 2574 7682 0.14 0.37 0.11 0.01 0
Diathermy vaporisation +
holmium enucleation
413 713 13 163 921 041 1385 9505 0 0.57 0.85 0.80 0.49
Diathermy vaporisation +
TURP repeated once if
necessary
418 264 4551 921 091 50 90 576 0 0.01 0.04 0.19 0.5
Reference strategy
TURP repeated once if
necessary
457 866 39 602 920 340 −751 Dominated 0 0 0 0.01 0.01
QALY=quality adjusted life year; N/A=not applicable; TURP=transurethral resection of prostate.
*Excludes other strategies dominated at a willingness to pay threshold of £20 000/QALY.
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Deterministic analysis
We also conducted one way sensitivity analysis to test
particular assumptions in themodel to test the effect on
outcome. These included discount rate, use of a life-
time horizon, use of a single cohort design to estimate
outcome for an individual over 10 years, use of relative
risk of reoperation instead of lack of symptomatic
improvement to estimate relapse rates, need for urody-
namic studies after relapse after diathermy or laser
vaporisation, and inclusion of results from studies per-
formed outside the UK to calculate length of stay and
complication rates.
RESULTS
Cost effective treatment strategies
The strategy of initial diathermy vaporisation followed
by holmium laser enucleation for men whose symp-
toms fail to improve or relapse after initial benefit was
cost effective with a probability of 0.85 at a willingness
to pay threshold of £20 000/QALY gained (table 5,
figure). In general, the use of escalating multiple treat-
ment strategies, starting with the option of diathermy
vaporisation, showed increased effectiveness and
decreased cost. Both diathermy vaporisation followed
byholmium laser enucleation anddiathermyvaporisa-
tion followed by transurethral resection, repeated if
necessary, dominated (that is, were more effective
and less costly) than other strategies, including the
reference standardof transurethral resection.The strat-
egy of diathermy vaporisation followed by transure-
thral resection repeated if necessary became cost
effective if the willingness to pay threshold was >
£80 000/QALY gained. Diathermy vaporisation as a
single treatment was not dominated and highly likely
to be cost effective at a willingness to pay threshold of
£5000/QALY gained. Holmium laser enucleation as a
single treatment dominated transurethral resection,
but the probability of it being the most cost effective
strategy never exceeded 0.37. All strategies starting
with microwave thermotherapy were dominated, as
were those involving potassium titanyl phosphate
laser vaporisation.Direct comparisonbetween alterna-
tive strategies and the reference strategy of transure-
thral resection, repeated if necessary, gave similar
results.
Sensitivity analysis
Model parameters
Tables 6, 7, and 8 show the results of one way sensitiv-
ity analyses. If we derived the probability used to pre-
dict treatment failure from reoperation rates, as
suggested by meta-analysis, then holmium laser enu-
cleation as a single treatment became extendedly
dominated by strategies startingwith diathermyvapor-
isation. If length of stay for transurethral resection was
reduced from three to two days then the current refer-
ence strategy of transurethral resection, repeated if
needed,was no longer dominated bydiathermyvapor-
isation. If performanceof urodynamicswasmademan-
datory for treatment failure after diathermy
vaporisation then the standard strategyof transurethral
resection, repeated if necessary,was not dominatedbut
had an incremental cost perQALYgainedof £230 608.
Using a single cohort of 25 000 men generally showed
similar incremental cost effectiveness ratios (ICER) for
non-dominated strategies except for diathermy vapor-
isation followed by transurethral resection, repeated if
necessary. Variation of all other parameters did not
alter conclusions drawn from base case analysis.
Effect of disaggregation
Calculation of time spent in each health state during
treatment strategies showed that most time was spent
in remission (table 9). This was shortest after either
microwave thermotherapy or potassium titanyl phos-
phate laser vaporisation and longest for sequences
starting with diathermy vaporisation.
DISCUSSION
Cost effective treatment
A strategy for surgical treatment of lower urinary tract
symptoms, presumed to be caused by benign prostatic
enlargement, consisting of initial ablation with dia-
thermy vaporisation followed by holmium laser enu-
cleation for those men who experienced treatment
failure or subsequent symptom relapse is cost effective
given a willingness to pay threshold of £20 000/QALY
gained. This conclusion was unchanged by extensive
sensitivity analysis. The model did not show any
advantage for strategies involving microwave thermo-
therapy, consistent with results of previous studies
modelling cost effectiveness of single minimally inva-
sive treatments including microwave
thermotherapy,7 26 27 transurethral needle ablation,8
and laser coagulation.26-28 Although diathermy vapor-
isation as a single treatment was not dominated, it was
less effective than transurethral resection and the
results were sensitive to small changes in the care
Willingness to pay (£/QALY gained)
Pr
ob
ab
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it
y
0
10
 00
0
20
 00
0
30
 00
0
40
 00
0
50
 00
0
60
 00
0
70
 00
0
80
 00
0
90
 00
0
10
0 0
00
0
0.2
0.4
0.6
0.8
1.0
Diathermy vaporisation
Transurethral resection
Holmium laser enucleation
Transurethral resection repeated once
Diathermy vaporisation + holmium laser enucleation
Diathermy vaporisation + transurethral resection repeated once
Cost effectiveness acceptability curve showing probability of
being cost effective for non-dominated and reference
strategies for increasing limits of willingness to pay
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pathway, making it unlikely to be advantageous in
practice. Single treatment with holmium laser enuclea-
tion was cost effective only at a threshold of between
£7600 and £9500 and its probability of being cost effec-
tive was never greater than 0.37. In addition, it is a
technically demandingprocedure requiring prolonged
training and a high level of competency to avoid ser-
ious adverse effects such as urinary sphincter damage
and bladder perforation. It is therefore probably
unsuited to widespread application and best used as
the final part of a treatment sequence, administered in
a few specialist centres for menwho relapse after trans-
urethral resection or vaporisation. It also became
dominated by diathermy vaporisation led strategies
when we recalculated reoperation rates.
The finding that potassium titanyl phosphate laser
vaporisation was unlikely to be cost effective, either
as a single treatment or within a treatment sequence,
is important as the procedure has gainedwide popular-
ity around the world because of its perceived ease of
use and reduced risk of bleeding and despite the lack of
evidence of equivalent or improved effectiveness over
transurethral resection. Although we obtained out-
come parameters for this option from the single eligi-
ble published trial involving potassium titanyl
phosphate laser vaporisation available at the time of
our meta-analysis and from other trials involving
vaporisation using alternative lasers, the finding was
unchanged by sensitivity analysis around uncertainty
in treatment benefit. In addition, a subsequent publica-
tion has noted reduced efficacy and increased retreat-
ment rates compared with transurethral resection.29
This option was also associated with relatively high
cost because of the need for one or more disposable
optical fibres, but again the conclusions were not
altered by sensitivity analysis around this variable
and were not compensated by reduced length of stay
or savings from the reduced complication rate. This
result, based on current evidence, therefore does not
support its current unrestricted use in clinical practice.
Use of strategies
Sequences of escalating treatmentsweremore effective
than single treatments, and this supports the need to
compare clinically plausible strategies as well as one-
off treatments in clinical trials. This policy of care
would be particularly attractive for large centrally
managed healthcare systems, such as the UK NHS,
whereby widespread use of a less morbid, technically
less demanding, and cheaper option, such as dia-
thermy vaporisation, could be widely offered as the
initial treatment in various settings, whereas holmium
Table 6 | Results of sensitivity analysis* showing effects on cost effectiveness of variation in start age and utility value for
state of incontinence
Treatment strategy Cost (£) Incremental cost (£)
Effectiveness
(QALYs)
Incremental
effectiveness
(QALYs)
Incremental cost
effectiveness ratio
(£/QALYs)
Base case
Diathermy vaporisation 380 774 844 — 917 082 — —
Holmium laser enucleation 400 549 783 19 774 939 919 656 2574 7682
Diathermy vaporisation + holmium laser
enucleation
413 712 972 13 163 189 921 041 1385 9505
Diathermyvaporisation+TURP repeated
once if necessary
418 264 231 4 551 258 921 091 50 90 576
Start age 90
Diathermy vaporisation 376 991 192 541 771
Holmium laser enucleation 397 495 122 20 503 931 543 268 1497 13 695
Diathermy vaporisation + holmium laser
enucleation
405 702 102 8 206 980 543 703 435 18 872
Diathermy vaporisation + TURP 409 475 528 3 773 426 543 715 12 309 087
Start age 50
Diathermy vaporisation 381 248 895 — 1 002 040 — —
Holmium laser enucleation 400 940 948 19 692 053 100 4857 2818 6988
Diathermy vaporisation + holmium laser
enucleation
414 850 642 13 909 693 100 6451 1594 8727
Diathermyvaporisation+TURP repeated
once if necessary
419 518 524 4 667 882 100 6511 59 78 771
Utility of “incontinence-no remission” = utility of “incontinence-remission”
Diathermy vaporisation 380 774 844 917 131 — —
Holmium laser enucleation 400 549 783 19 774 939 919 679 2548 7762
Diathermy vaporisation + holmium
vaporisation
413 712 972 13 163 189 921 092 1413 9315
Diathermyvaporisation+TURP repeated
once if necessary
418 264 231 4 551 258 921 144 52 88 045
QALY=quality adjusted life year; TURP=transurethral resection of prostate.
*Based on 10 000 Monte Carlo simulation samples and showing only non-dominated and non-extendedly dominated strategies.
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laser enucleation, with its need for highly skilled opera-
tors, would be available in a limited number of specia-
lised units to treat the relatively small number of men
who fail to benefit or relapse after a vaporisation pro-
cedure. The findings of our study and associated sys-
tematic reviews45 suggest the need for longer termhigh
quality trials to test the worth of such sequences of
newer treatment. A multicentre head-to-head rando-
mised controlled trial of this strategy against the stan-
dard of transurethral resection, repeated as needed,
followed by a longer term “tracker” trial of the newer
technologies should particularly assess the need, rea-
son, and chosen technique for retreatment after failure
or relapse. The design would need to be flexible to
encompass new technologies as they emerge and
account for changes in current technology, such as
increased power and reduced fibre cost for laser vapor-
isation, and should be sufficiently powered to reduce
uncertainty regarding cost effectiveness. To better
judge cost effectiveness it would be necessary to con-
sider inmore detail how symptom scoresmap to utility
values and howQALY gains estimated by disease spe-
cific symptom scores compare with estimates by using
a generic instrument such as theEQ-5D.Calculation of
utility values would be strengthened by qualitative
research components to record preferences of indivi-
dual men concerning the trade-off between reduced
treatment morbidity and increased risk of reoperation.
Uncertainties
Although we have used the best available methods to
define the likely outcomes of each treatment, limita-
tions in the current evidence base lead to inevitable
uncertainty regarding parameter values. Reassuringly,
sensitivity analysis around appropriately selected vari-
ables did not radically change key outcomes of the
model. Calculation of the expected value of perfect
information according to standard practice30 suggested
that an upper overall limit of £5.3m should be spent on
further research to give worthwhile benefit, with speci-
fic studies of vaporisation techniques and holmium
laser enucleation having upper limits of £4.2m and
£1.7m, respectively. These values are based on perfect
rather than sample basedevidence and therefore future
trials should be carefully planned to deliver the
required answerwell within these financial constraints.
Strengths of the model
We have considered a wide variety of treatment
sequences of relevance to healthcare consumers and
providers in differing healthcare systems. The inclu-
sion of minimally invasive treatments, for example, is
most relevant to clinical practice in theUS and Scandi-
navia, while holmium enucleation is mostly used in
Europe and Australasia. We have also accounted for
continued changes in clinical practice by including
well researched but currently unpopular options such
Table 7 | Results of sensitivity analysis* showing effects on cost effectiveness of variation in utility value of remission, risk of
adverse events, length of stay, and calculation of risk of need for repeat surgery
Treatment strategy Cost (£) Incremental cost (£)
Effectiveness
(QALYs)
Incremental
effectiveness
(QALYs)
Incremental cost
effectiveness ratio
(£/QALYs)
Utility of IPSS <8 is 0.97
Diathermy vaporisation 380 774 844 893 516
Holmium laser enucleation 400 549 783 19 774 939 894 844 1328 14 889
Diathermy vaporisation + holmium
vaporisation
413 712 972 13 163 189 895 584 740 17 791
Diathermyvaporisation+ TURP repeated
once if necessary
418 264 231 4 551 258 895 611 28 163 682
Relative risk of adverse events from all studies
Diathermy vaporisation 380 774 844 917 082
Holmium laser enucleation 400 549 783 19 774 939 919 656 2574 7682
Diathermy vaporisation + holmium
vaporisation
413 712 972 13 163 189 921 041 1385 9505
Length of stay for TURP = length of stay for diathermy vaporisation = 2 days
Diathermy vaporisation 376 715 152 917 082
TURP 380 679 392 3 964 240 918 222 1140 3476
TURP repeated once if necessary 400 362 758 19 683 366 920 340 2117 9296
Diathermyvaporisation+ TURP repeated
once if necessary
409 495 593 9 132 834 921 091 751 12 156
Alternative calculation of probability of failure
Diathermy vaporisation 380 793 296 918 558
Diathermy vaporisation + holmium
vaporisation
404 008 222 23 214 926 921 217 2659 8731
Diathermyvaporisation+ TURP repeated
once if necessary
406 972 673 2 964 451 921 269 52 56 845
QALY=quality adjusted life year; IPSS=international prostate symptom score; TURP=transurethral resection of prostate.
*Based on 10 000 Monte Carlo simulation samples and showing non-dominated and non-extendedly dominated strategies only.
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as diathermy vaporisation as well as recently intro-
duced but less well evaluated procedures such as potas-
sium titanyl phosphate laser vaporisation. Our model
was based on a rigorous systematic review of the inter-
national literature. We also made strenuous efforts to
be transparent in our reporting, which should allow
researchers and decision makers to make judgments
about the applicability of the work to their own set-
tings. The use of a multiple cohort model allowed con-
sideration of the diseconomies associated with using a
costly, capital intensive second or third line treatment
by simulating the purchasing of new equipment as
required over the time horizon and avoided bias inher-
ent in the allocation of capital costs across the whole
population and time period using a single cohort tech-
nique. As a result, we believe that this model gives
improved meaning regarding the effects of changing
treatment policy for decision makers as well as clini-
cians.
Limitations of the model
Initially, we included in the model other procedures
identified in the systematic review—such as bipolar
diathermy resection and holmium laser vaporisation
—but the number of possible treatment sequences
became unmanageable and we therefore focused on
technologies in current wide use or those with an
extensive evidence base. Selection between vaporisa-
tion techniques with different energy sources pre-
sented a difficulty, with diathermy having the greatest
evidence base but potassium titanyl phosphate laser
currently being the most popular. Both were run in
the model and the result in terms of cost effectiveness
was markedly in favour of diathermy, despite its cur-
rent unpopularity.Given that these techniques achieve
the same surgical result in terms of tissue ablation it is
likely that a future laser procedure,which replicates the
treatment benefit and low cost of diathermy, could take
its placewithin the sequenceof cost effective treatment.
The probability of failure for treatments under study
was a key parameter but difficult to quantify with cer-
tainty; lack of change in symptoms was the preferred
definition but it was uncertain how this was reflected in
reoperation rates published in the literature, which dif-
fered between studies. Our resolution was to use indi-
vidual level data, and this seemed valid because a
sensitivity analysis with a different approach gave lar-
gely consistent results. The use of a threshold of <10%
improvement in symptoms reflected the definite need
for further surgery as distinct from other definitions of
treatment success used in trials of treatment. It would,
however, be important to validate this threshold in
future studies by prospectively recording reasons for
retreatment. Mapping of symptom scores to utility
values was another difficulty, which we resolved by
synthesising available data. Again sensitivity analysis
suggests that our approach was reasonable, although
the need for further research in this area is acknowl-
edged.
Costs were deliberately based on the setting of the
NHS in England because this provided the most com-
prehensive source of data, and, again, sensitivity ana-
lysis suggests that the choices made were robust,
although translation to other healthcare systems
might not be clear cut. We did not consider costs asso-
ciated with staff retraining and service reconfiguration
required to change practice away from the standard of
transurethral resection, but these are likely to be small
if the cost effective strategy of vaporisation followed by
holmium resection in the case of failure or relapse is
adopted as sufficient capacity already exists. Any
healthcare provider, however, would need to consider
the opportunity cost of switching funding fromanother
area to implement the policy change.
Table 8 | Results of sensitivity analysis* showing effects on cost effectiveness of variation in use of urodynamic test after
failed surgery and use of single cohort model
Treatment strategy Cost (£) Incremental cost (£)
Effectiveness
(QALYs)
Incremental
effectiveness
QALYs)
Incremental cost
effectiveness ratio
(£/QALYs)
Urodynamic test mandatory after failed diathermy vaporisation
Diathermy vaporisation 380 774 844 — 917 082 — —
Holmium laser enucleation 400 549 783 19 774 939 919 656 2574 7682
Diathermy vaporisation + holmium
vaporisation
405 478 440 4 928 657 920 051 395 12 475
Diathermy vaporisation+ TURP repeated
once if necessary
409 175 523 3 697 083 920 128 78 47 659
TURP repeated once if necessary 457 866 096 48 690 573 920 340 211 230 608
Single cohort model
Diathermy vaporisation 1794 7.12
Holmium laser enucleation 1819 25 7.14 0.0202 1 242
Diathermy vaporisation + holmium
vaporisation
1958 139 7.15 0.0129 10 755
Diathermy vaporisation+ TURP repeated
once if necessary
1990 31 7.15 0.0005 60 896
QALY=quality adjusted life year; TURP=transurethral resection of prostate.
*Based on 10 000 Monte Carlo simulation samples and showing non-dominated and non-extendedly dominated strategies only.
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The population studied in themodel was sufficiently
healthy to undergo any of the procedures. In practice,
menwith comorbidities resulting in an excessive risk of
bleeding or fluid imbalance tend to be advised against
transurethral resection. For these men, less morbid
procedures, such asmicrowave therapy and potassium
titanyl phosphate laser vaporisation, offer the opportu-
nity for treatment and indeed are in widespread use for
this indication, but inclusion of this scenario would
have greatly increased the complexity of our model.
Our remit was focused on surgical treatment and we
therefore assumed that men entering the model had
already tried and failed conservative management in
the form of advice on fluid management or drug treat-
ment. In future research it would be useful to add these
options at the start of treatment strategies to determine
overall cost effectiveness of all options available for the
management of this condition.
Conclusion
Current evidence suggests a sequence of treatments
consisting of initial diathermy vaporisation followed
by either holmium laser enucleation or transurethral
resection, repeated if necessary on failure or relapse,
Table 9 | Time spent in each state of Markov model for base case disaggregated from quality of life and ranked in
descending order according to time in remission state
Treatment strategy
Time in health state* (years)
Treatment Remission No remission Incontinence† Death
Diathermy vaporisation + TURP repeated once
if necessary‡
0.27 7.92 0.04 0.09 1.67
Diathermy vaporisation + holmium laser
enucleation‡
0.27 7.91 0.05 0.09 1.67
Diathermy vaporisation + TURP 0.27 7.89 0.07 0.09 1.67
TURP repeated once if necessary§ 0.26 7.78 0.18 0.10 1.67
Microwave thermotherapy + diathermy
vaporisation + TURP
0.36 7.75 0.13 0.09 1.67
Microwave thermotherapy + diathermy
vaporisation + TURP repeated once if
necessary
0.36 7.75 0.12 0.09 1.67
Microwave thermotherapy + diathermy
vaporisation + holmium laser enucleation
0.36 7.75 0.12 0.09 1.67
Microwave thermotherapy + TURP repeated
once if necessary
0.36 7.71 0.16 0.09 1.67
Microwave thermotherapy repeated once+
diathermy vaporisation + TURP
0.40 7.68 0.16 0.09 1.67
Microwave thermotherapy repeated once +
diathermy vaporisation + TURP repeated once
if necessary
0.40 7.68 0.16 0.09 1.67
Microwave thermotherapy + holmium laser
enucleation
0.35 7.68 0.21 0.09 1.67
Microwave thermotherapy repeated once +
diathermy vaporisation + holmium laser
enucleation
0.40 7.68 0.16 0.09 1.67
Microwave thermotherapy repeated once +
TURP repeated once if necessary
0.40 7.67 0.17 0.09 1.67
Microwave thermotherapy repeated once +
holmium laser enucleation
0.40 7.66 0.19 0.09 1.67
Holmium laser enucleation‡ 0.25 7.65 0.33 0.09 1.67
Microwave thermotherapy repeated once +
TURP
0.40 7.63 0.21 0.09 1.67
Microwave thermotherapy repeated once +
diathermy vaporisation
0.40 7.62 0.23 0.08 1.67
Microwave thermotherapy + TURP 0.35 7.61 0.27 0.09 1.67
Microwave thermotherapy + diathermy
vaporisation
0.35 7.56 0.33 0.08 1.67
TURP§ 0.25 7.44 0.55 0.09 1.67
Diathermy vaporisation† 0.25 7.27 0.72 0.09 1.67
Microwave thermotherapy repeated once 0.35 6.82 1.08 0.08 1.67
Potassium titanyl phosphate vaporisation 0.25 5.65 2.21 0.21 1.67
Microwave thermotherapy 0.25 5.28 2.74 0.06 1.67
TURP=transurethral resection of prostate.
*Not discounted.
†Includes “incontinence-no remission” and “incontinence-remission.”
‡Non-dominated strategy.
§Reference strategy.
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are cost effective strategies for surgical treatment of
symptoms presumed to be caused by benign enlarge-
ment of the prostate. Given uncertainty about the will-
ingness to pay threshold for a gain in QALYs, single
treatment with either diathermy vaporisation or hol-
mium laser enucleation could also be cost effective.
Limitations in available data might affect the results
of the cost effectiveness analysis and additional oppor-
tunity costs might negate savings made by changing
from the current highly clinically effective established
standard of transurethral resection.
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